Lubrizol Life Science Health (LLS), a Berkshire Hathaway Company, has introduced its ASTAGILE microcapsules, its new sustainable, organic-certified, astaxanthin (Haematococcus pluvialis), microencapsulated with spirulina, it was reported on Wednesday.
Both ingredients have been combined in a patent-pending product aimed to promote mental agility and support healthy ageing for young and senior adults.
Astaxanthin is a carotenoid found in freshwater microalgae, while spirulina is a type of algae. In order to create the synergistic algae blend, LLS Health collaborated with Neoalgae Micro Seaweeds Products, SL, a research and development company in Spain dedicated to microalgae biotechnology. LLS claims that recent studies showed the cognitive enhancement effects of ASTAGILE, including a boost in memory performance, cognition and learning capabilities, and provided antioxidant and anti-inflammatory protection to the brain.
Biophytis secures Brazilian funding and partnerships for obesity Phase 2 trial
Phrontline Biopharma doses first patient in TJ101 Phase 1 clinical trial
Gene Solutions' mitochondrial therapy platform targeting neurological diseases secures patent
Zhimeng Biopharma's investigational drug gains Phase 2 epilepsy clinical trial approval in China
Avidity Biosciences prices upsized common stock public offering
Sanofi's SAR402663 granted FDA fast track designation for wet AMD
Endo to share PFI and PFA data at American Orthopaedic Foot & Ankle Society Annual Meeting
Diamyd Medical secures Eurasian patent for insulin-based antigen therapy in type 1 diabetes
Sobi's Biologics License Application for NASP in uncontrolled gout accepted by FDA
Hydrosome Labs announces promising fermentation breakthrough with ultrafine bubbles
Ionis receives FDA Breakthrough Therapy designation for ION582 in Angelman syndrome
AMO Pharma signs licence agreement with PHRI and Venca Research Inc to advance new study in ARVC
Saol Therapeutics receives US FDA Complete Response Letter for SL1009 (DCA) in PDCD